Losartan, 50 mg 30 pcs

Heart failure, Prevention of heart attacks and strokes, Hypertension (high blood pressure)

Indications

Arterial hypertension.

Reduced risk of associated cardiovascular morbidity and mortality in patients with arterial hypertension and left ventricular hypertrophy, manifested by a combined reduction in the incidence of cardiovascular mortality, stroke and myocardial infarction.

Kidney protection in patients with type 2 diabetes mellitus with proteinuria – slowing the progression of renal failure, manifested by a decrease in the incidence of hypercreatininemia, the incidence of end-stage chronic renal failure requiring hemodialysis or kidney transplantation, mortality rates, as well as a decrease in proteinuria.

Chronic heart failure (as part of combination therapy, with intolerance or ineffectiveness of therapy with ACE inhibitors).

Pharmacological effect

Pharmacotherapeutic group: Angiotensin II receptor antagonist

Pharmacological action

Antihypertensive agent. It is a non-peptide angiotensin II receptor blocker. It has high selectivity and affinity for AT1 type receptors (with the participation of which the main effects of angiotensin II are realized). By blocking these receptors, losartan prevents and eliminates the vasoconstrictor effect of angiotensin II, its stimulating effect on the secretion of aldosterone by the adrenal glands and some other effects of angiotensin II. It is characterized by a long-term effect (24 hours or more), which is due to the formation of its active metabolite.

Pharmacokinetics

After oral administration, losartan is rapidly absorbed from the gastrointestinal tract. Bioavailability is about 33%. Metabolized during the “first pass” through the liver to form a carboxyl metabolite, which has more pronounced pharmacological activity than losartan, and a number of inactive metabolites. Cmax in blood plasma of losartan and the active metabolite is achieved after 1 hour and 3-4 hours, respectively. Plasma protein binding of losartan and the active metabolite is high – more than 98%.

T1/2 of losartan and the active metabolite in the final phase is about 1.5-2.5 hours and 3-9 hours, respectively. Losartan is excreted in the urine and feces (with bile) unchanged and in the form of metabolites. About 35% is excreted in urine and about 60% in feces.

Special instructions

Use with caution in case of arterial hypotension, decreased blood volume, water-electrolyte imbalance, bilateral renal artery stenosis or stenosis of the artery of a single kidney, in case of renal/liver failure

Patients who have fluid and/or sodium deficiency should have their fluid and electrolyte imbalances corrected or use a lower initial dose before starting treatment.

In patients with dehydration (eg, those receiving high-dose diuretics), symptomatic hypotension may occur when losartan treatment is initiated.

If renal function is impaired, a dose reduction of losartan may be required.

In patients with a history of liver disease, losartan should be used in low doses. In liver cirrhosis, the concentration of losartan in the blood plasma increases significantly.

During treatment, potassium levels in the blood should be regularly monitored, especially in elderly patients with impaired renal function.

The simultaneous use of losartan with potassium-sparing diuretics should be avoided.

The safety and effectiveness of losartan in children have not been established.

Active ingredient

Losartan

Composition

Active substance: losartan

Excipients: lactose monohydrate 190.1 mg, microcrystalline cellulose 57 mg, povidone 13.3 mg, magnesium stearate 3.8 mg, croscarmellose sodium 15.8 mg.

Pregnancy

Contraindicated for use during pregnancy and lactation.

Contraindications

Pregnancy, lactation, childhood and adolescence under 18 years of age, hypersensitivity to losartan.

Side Effects

From the cardiovascular system: dizziness, orthostatic hypotension.

Metabolism: hyperkalemia.

Allergic reactions: angioedema (including swelling of the face, lips, pharynx and/or tongue), urticaria.

From the digestive system: diarrhea, increased ALT activity.

From the side of the central nervous system: headache.

Dermatological reactions: itching.

Other: renal dysfunction, myalgia.

Interaction

When used simultaneously with diuretics in high doses, arterial hypotension is possible.

When used simultaneously with potassium preparations and potassium-sparing diuretics, the risk of developing hyperkalemia increases.

When used simultaneously with indomethacin, the effectiveness of losartan may be reduced.

There is a report of the development of lithium intoxication when used simultaneously with lithium carbonate.

When used simultaneously with orlistat, the antihypertensive effect of losartan decreases, which can lead to a significant increase in blood pressure and the development of a hypertensive crisis.

When used simultaneously with rifampicin, the clearance of losartan increases and its effectiveness decreases.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C.

Manufacturer

Ozon, Russia